166 related articles for article (PubMed ID: 26376647)
1. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
[TBL] [Abstract][Full Text] [Related]
6. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
[TBL] [Abstract][Full Text] [Related]
7. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
[TBL] [Abstract][Full Text] [Related]
8. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
[TBL] [Abstract][Full Text] [Related]
9. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.
Zhou Q; Geng Q; Wang L; Huang J; Liao M; Li Y; Ding Z; Yang S; Zhao H; Shen Q; Pan C; Lou J; Lu S; Chen C; Luo Q
EBioMedicine; 2019 Mar; 41():236-243. PubMed ID: 30872130
[TBL] [Abstract][Full Text] [Related]
10. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.
Li XJ; Hayward C; Fong PY; Dominguez M; Hunsucker SW; Lee LW; McLean M; Law S; Butler H; Schirm M; Gingras O; Lamontagne J; Allard R; Chelsky D; Price ND; Lam S; Massion PP; Pass H; Rom WN; Vachani A; Fang KC; Hood L; Kearney P
Sci Transl Med; 2013 Oct; 5(207):207ra142. PubMed ID: 24132637
[TBL] [Abstract][Full Text] [Related]
11. Coexisting pulmonary nodules in operable lung cancer: prevalence and probability of malignancy.
Ruppert AM; Lerolle U; Carette MF; Lavole A; Khalil A; Bazelly B; Antoine M; Cadranel J; Milleron B
Lung Cancer; 2011 Nov; 74(2):233-8. PubMed ID: 21511355
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
[TBL] [Abstract][Full Text] [Related]
13. Validation of a multiprotein plasma classifier to identify benign lung nodules.
Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital.
Cui X; Han D; Heuvelmans MA; Du Y; Zhao Y; Zhang L; Groen HJM; de Bock GH; Dorrius MD; Oudkerk M; Vliegenthart R; Ye Z
Cancer Biol Med; 2020 Feb; 17(1):199-207. PubMed ID: 32296586
[No Abstract] [Full Text] [Related]
15. Evaluation and management of solitary and multiple pulmonary nodules.
Viggiano RW; Swensen SJ; Rosenow EC
Clin Chest Med; 1992 Mar; 13(1):83-95. PubMed ID: 1582151
[TBL] [Abstract][Full Text] [Related]
16. [Value of Combined Detection of Cytokines and Tumor Markers in the
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
[TBL] [Abstract][Full Text] [Related]
17. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
Li X; Zhang Q; Jin X; Cao L
World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy.
Kothary N; Lock L; Sze DY; Hofmann LV
Clin Lung Cancer; 2009 Sep; 10(5):360-3. PubMed ID: 19808195
[TBL] [Abstract][Full Text] [Related]
19. Shape-Sensing Robotic-Assisted Bronchoscopy versus Computed Tomography-Guided Transthoracic Biopsy for the Evaluation of Subsolid Pulmonary Nodules.
Fernandez-Bussy S; Yu Lee-Mateus A; Reisenauer J; Balasubramanian P; Barrios-Ruiz A; Garza-Salas A; Chandra NC; Koratala A; Nadrous A; Edell ES; Bowman AW; Grage RA; Reisenauer CJ; Kurup AN; Patel NM; Chadha R; Hazelett BN; Abia-Trujillo D
Respiration; 2024; 103(5):280-288. PubMed ID: 38471496
[TBL] [Abstract][Full Text] [Related]
20. Identification of preoperative prediction factors of tumor subtypes for patients with solitary ground-glass opacity pulmonary nodules.
Li M; Wang Y; Chen Y; Zhang Z
J Cardiothorac Surg; 2018 Jan; 13(1):9. PubMed ID: 29343293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
